<DOC>
	<DOCNO>NCT02485119</DOCNO>
	<brief_summary>The primary objective Phase I study 15404 evaluate safety , tolerability pharmacokinetics BAY94-9343 give every 3 week Japanese subject advance , refractory solid tumor . The secondary objective investigate efficacy , biomarkers immunogenicity .</brief_summary>
	<brief_title>Phase I Dose Escalation Study BAY94-9343 Given Intravenous Infusion Every 3 Weeks Japanese Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Japanese subject â‰¥ 20 year age ECOG Performance Status 0 1 Life expectancy least 12 week Subjects advance , histologically cytologically confirm solid tumor , amenable standard therapy , standard therapy available Subjects whose fresh archival tumor tissue available Measurable disease least one lesion accurately measure least one dimension accord RECIST criterion ( Version 1.1 modify version ) Adequate bone marrow , liver , renal function Anticancer chemotherapy , experimental cancer therapy , immunotherapy within 2 week start first dose Impaired cardiac function clinically significant cardiac disease ( i.e. , congestive heart failure ( CHF ) NYHA Class III IV ) Myocardial infarction onset unstable angina &lt; 3 month prior general screen Cardiac arrhythmia electrocardiogram would interfere QT/QTc interval measurement ( LBBB ( leave bundle branch block ) , AV block , atrial fibrillation ) QTc &gt; 470 m , derive average 3 value measure ECG recorder 's algorithm ECG triplicate LVEF ( leave ventricular ejection fraction ) &lt; 50 % Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mmHg , despite optimal medical management Known human immunodeficiency virus ( HIV ) infection Subjects active hepatitis B C infection require treatment Personal family history Long QT Syndrome ( LQTS ) Subject clinically significant eye disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BAY 94-9343</keyword>
	<keyword>Anetumab ravtansine</keyword>
	<keyword>ADC ( Antibody Drug Conjugate )</keyword>
	<keyword>Phase I</keyword>
	<keyword>Japan</keyword>
	<keyword>solid cancer</keyword>
	<keyword>Advanced , refractory solid tumor</keyword>
	<keyword>mesothelin</keyword>
	<keyword>endometrial</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>gastrointestinal , ovarian , pancreatic , cholangio , mesothelioma triple negative breast cancer</keyword>
</DOC>